Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polydiuretic therapy for HFpEF
NCT05129722Phase 4Terminated
- Sponsor
- The George Institute for Global Health
- Start
- Oct 2022
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of bumetanide, eplerenone, empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by The George Institute for Global Health. Started Oct 2022; status: terminated.
02
Drugs
bumetanideeplerenoneempagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05129722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129722.